From Bench to Product – We know how to facilitate development for medical progress
Are you responsible for a high-quality biotech product pipeline? On a daily basis you have to make high-stake decisions regarding your product development plan?
We know how to navigate in this uncertain and complex environment.
Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III. VPM achieved business proof of concept by successfully out-licensing three candidates out of five.
With the out-licensing of our products we shifted our business focus on consulting and services adding value to client projects based on our in-depth experience. For us, effective project management and sound product development plans are key for success. Our clients are small, medium and large biopharmaceutical enterprises, as well as private funding organizations, and research groups. Our consulting and service offers refer to the entire product development value chain as VPM has experienced and successfully mastered each of these value points for itself. We offer you our professional advice and support in the following areas:
- Regulatory Consultancy
- Translational Project Management
- Valuation & Due Diligence
- Organizational & Quality Management
- Clinical Trial Sponsorship
We understand how complex product development is, because we did it ourselves. Let us be a competent partner at your side for a secure route to a successful product
Our Service Models
VPM offers fee-for-service models for defined working packages out of our diverse service portfolio.
Our service on demand is ideal for companies that need support on short notice or within an area beyond their internal expertise.
Our clients have the opportunity of complementing their existing management with our experts over a designated period of time. This cooperation may also be based on a shared risk/benefit model.